^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    TNBCDX®

    Company:
    Reveal Genomics
    Type:
    Laboratory Developed Test
    Related tests:

    Details

    Evidence
    News
    TNBCDX® is the first genomic test designed specifically for patients with early-stage TNBC. The test integrates clinical variables with key tumor and immune biological factors across 15 genes to provide a comprehensive risk assessment, guiding treatment decisions in a clinical setting. TNBCDX® includes two scores: a risk score and a pCR (pathological complete response) likelihood score. Additionally, the test measures the levels of ERBB2 to ensure that the tumor is accurately classified as TNBC.
    Cancer:
    Triple Negative Breast Cancer